JO3097B1 - الأجسام المضادة c-Met - Google Patents

الأجسام المضادة c-Met

Info

Publication number
JO3097B1
JO3097B1 JOP/2009/0424A JOP20090424A JO3097B1 JO 3097 B1 JO3097 B1 JO 3097B1 JO P20090424 A JOP20090424 A JO P20090424A JO 3097 B1 JO3097 B1 JO 3097B1
Authority
JO
Jordan
Prior art keywords
met
met antibodies
pathogenesis
antigen
mediated
Prior art date
Application number
JOP/2009/0424A
Other languages
English (en)
Inventor
Edward Vaillancourt Peter
Davis Julian
Lu Jirong
Liu Ling
Andrew Wortinger Mark
Zeng Wei
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11682508P priority Critical
Priority to US21990309P priority
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3097B1 publication Critical patent/JO3097B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Abstract

يتعلق الاختراع الحالي بأجسام مضادة أحادية النسيلة، وشظيات ربط مولد ضد منها، وتوليفات مما سبق، ترتبط بـ c-Met وتثبط نشاطه، وتتسم بأنها فعالة في علاج أنواع السرطان والأمراض أو الاضطرابات أو الحالات الأخرى التي يساهم c-Met في الإصابة بها.
JOP/2009/0424A 2008-11-21 2009-11-15 الأجسام المضادة c-Met JO3097B1 (ar)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11682508P true 2008-11-21 2008-11-21
US21990309P true 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
JO3097B1 true JO3097B1 (ar) 2017-03-15

Family

ID=41435259

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0424A JO3097B1 (ar) 2008-11-21 2009-11-15 الأجسام المضادة c-Met

Country Status (27)

Country Link
US (2) US8217148B2 (ar)
EP (2) EP2963058B1 (ar)
JP (1) JP5688027B2 (ar)
KR (1) KR101334450B1 (ar)
CN (1) CN102216333B (ar)
AR (1) AR074360A1 (ar)
AU (1) AU2009316742B2 (ar)
BR (1) BRPI0922800A2 (ar)
CA (1) CA2743508C (ar)
CY (1) CY1116886T1 (ar)
DK (1) DK2358755T3 (ar)
EA (1) EA020398B1 (ar)
ES (2) ES2663825T3 (ar)
HK (1) HK1158229A1 (ar)
HR (1) HRP20151019T1 (ar)
HU (1) HUE026058T2 (ar)
IL (1) IL212633A (ar)
JO (1) JO3097B1 (ar)
MX (1) MX2011005400A (ar)
NZ (1) NZ592215A (ar)
PA (1) PA8849001A1 (ar)
PT (1) PT2358755E (ar)
SI (1) SI2358755T1 (ar)
TR (1) TR201802841T4 (ar)
TW (1) TWI477284B (ar)
WO (1) WO2010059654A1 (ar)
ZA (1) ZA201103586B (ar)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
WO2011150454A1 (en) * 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
CA2808236A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP2611928B1 (en) * 2010-09-03 2016-04-27 Academia Sinica Anti-c-met antibody and methods of use thereof
CN103764678A (zh) 2010-11-03 2014-04-30 阿尔金-X公司 c-Met抗体组合
CN102276726B (zh) * 2011-03-16 2014-02-19 常州新泉生物医药科技有限公司 肝细胞生长因子受体活性基团的融合蛋白
US20140301989A1 (en) * 2011-06-17 2014-10-09 Brian Johnstone Methods for increasing the potency and efficacy of stem cells
BR112014006419A2 (pt) 2011-09-19 2018-08-07 Genentech Inc métodos para tratar um paciente com câncer, kit e artigo
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 c-Met 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 c-Met 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
CA2854477A1 (en) 2011-11-21 2013-05-30 Genentech, Inc. Purification of anti-c-met antibodies
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
ES2641444T3 (es) * 2012-05-09 2017-11-10 Eli Lilly And Company Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
DK2766048T3 (en) 2012-10-12 2015-03-02 Spirogen Sarl Pyrrolobenzodiazepins and conjugates thereof
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR20140119317A (ko) * 2013-03-28 2014-10-10 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
EP2992019B1 (en) * 2013-04-30 2019-03-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
BR112016003057A2 (pt) * 2013-08-14 2017-11-21 Qiagen Mansfield Inc composições e métodos para análise multimodal de ácidos nucleicos cmet
CN105899226A (zh) * 2013-10-14 2016-08-24 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) 2013-12-23 2016-03-16 Lilly Co Eli 結合egfr及met之多功能抗體
TW201622744A (zh) * 2014-03-04 2016-07-01 Lilly Co Eli 癌症之組合療法
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
CN106661622A (zh) 2014-05-23 2017-05-10 豪夫迈·罗氏有限公司 Mit生物标志物和使用它们的方法
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CA2961323A1 (en) * 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN108601834A (zh) * 2016-02-05 2018-09-28 百疗医株式会社 抗间质-上皮细胞转化因子抗体及其用途
GB2551372A (en) * 2016-06-16 2017-12-20 Bombardier Primove Gmbh A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
US10439449B2 (en) * 2016-08-10 2019-10-08 Microsoft Technology Licensing, Llc Coupling device modules for inductive data transmission
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN109963562A (zh) 2016-11-16 2019-07-02 伊莱利利公司 用于具有外显子14跳读突变或外显子14跳读表型的癌症的组合疗法
TW201831514A (zh) * 2016-11-16 2018-09-01 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
CN110022903A (zh) 2016-11-23 2019-07-16 伊莱利利公司 Met抗体药物缀合物
TW201825515A (zh) * 2017-01-04 2018-07-16 美商伊繆諾金公司 Met抗體以及其免疫結合物及用途
CN109771642A (zh) * 2017-11-13 2019-05-21 同济大学苏州研究院 c-MET激动型抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0520158A1 (en) * 1991-05-10 1992-12-30 PHARMACIA S.p.A. Truncated forms of the hepatocyte growth factor (HGF) receptor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE60011612T2 (de) 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it) * 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
DE602005020799D1 (de) 2004-08-05 2010-06-02 Genentech Inc Humanisierte anti-cmet-antagonisten
WO2006104911A2 (en) 2005-03-25 2006-10-05 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
SG169382A1 (en) 2006-02-06 2011-03-30 Metheresis Translational Res S A Ch Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
JP2009529000A (ja) 2006-02-22 2009-08-13 イーライ リリー アンド カンパニー ヒト化抗グレリン抗体
AU2007245181A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-hgf/sf 인간화 항체 및 이의 제조방법
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR20090113325A (ko) * 2007-02-08 2009-10-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 흑색종에서의 gnaq 돌연변이
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met

Also Published As

Publication number Publication date
EP2963058B1 (en) 2018-02-21
CA2743508A1 (en) 2010-05-27
HK1158229A1 (zh) 2016-01-08
EA201170716A1 (ru) 2011-12-30
EP2963058A1 (en) 2016-01-06
CN102216333B (zh) 2014-05-21
HUE026058T2 (en) 2016-05-30
PT2358755E (pt) 2015-11-12
IL212633A (en) 2015-03-31
US20100129369A1 (en) 2010-05-27
TW201023885A (en) 2010-07-01
KR20110074612A (ko) 2011-06-30
AU2009316742B2 (en) 2012-06-07
AR074360A1 (es) 2011-01-12
ES2549760T3 (es) 2015-11-02
NZ592215A (en) 2012-09-28
TWI477284B (zh) 2015-03-21
MX2011005400A (es) 2011-06-20
JP5688027B2 (ja) 2015-03-25
US8398974B2 (en) 2013-03-19
EA020398B1 (ru) 2014-10-30
KR101334450B1 (ko) 2013-12-02
ES2663825T3 (es) 2018-04-17
SI2358755T1 (sl) 2015-10-30
DK2358755T3 (en) 2015-11-16
PA8849001A1 (es) 2010-06-28
ZA201103586B (en) 2013-10-30
WO2010059654A1 (en) 2010-05-27
US8217148B2 (en) 2012-07-10
HRP20151019T1 (en) 2015-10-23
AU2009316742A1 (en) 2010-05-27
CN102216333A (zh) 2011-10-12
CY1116886T1 (el) 2017-04-05
TR201802841T4 (tr) 2018-03-21
EP2358755A1 (en) 2011-08-24
EP2358755B1 (en) 2015-09-02
CA2743508C (en) 2016-07-19
BRPI0922800A2 (pt) 2015-12-22
US20120263723A1 (en) 2012-10-18
JP2012509881A (ja) 2012-04-26
IL212633D0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
JO2913B1 (ar) اجسام مضادة موجهة نحو بروتينات انجيوبويتين -1 وانجيوبويتين-2 واستخداماتها
EA200802168A1 (ru) Гуманизированное антитело к с-kit
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MX2015003206A (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos.
WO2009052081A4 (en) Antibodies that bind il-4 and/or il-13 and their uses
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
CY1120102T1 (el) Συνθεσεισ και μεθοδοι για μειωση τριγλυκεριδιων χωρισ αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονησ θεραπειασ στατινησ
MXPA04008870A (es) Anticuerpos anti-avb6.
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
SG191639A1 (en) Dual variable domain immunoglobulins and uses thereof
NZ595235A (en) Compositions and methods for increasing muscle growth
GT201200125A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
AT551071T (de) Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
MX2007016307A (es) Tratamiento de condiciones inflamatorias.
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
UA114604C2 (uk) Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)
EP2542582A4 (en) Therapeutic dll4 binding proteins
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
CY1119097T1 (el) Σιωπηλεσ παραλλαγεσ fc των anti-cd40 αντισωματων
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof